Abstract:
OBJECTIVE To investigate the pharmacological basis and mechanism of action of Compound Jiemin decoction(JMD) in the treatment of allergic rhinitis(AR) in children using a combination of serum medicinal chemistry and network pharmacology.
METHODS The blood components of JMD were identified by UHPLC-Q-Exactive Orbitrap MS/MS, combined with BiotreeDB V3.0 database and control comparison. The protein-protein interaction network was constructed by network pharmacology, combined with the ‘drug-component-target-disease’ analysis, GO functional analysis, KEGG enrichment analysis and molecular docking techniques to reveal the key active components and potential mechanism of action of JMD in the treatment of AR in children.
RESULTS A total of 115 compounds were identified in the JMD extracts, of which 75 components were found in serum. The results of the network pharmacological research showed that JMD had 176 potential targets for the treatment of AR in children, which might act on the core targets such as TNF, IL6, AKT1, STAT3, EGFR, and regulate Th17 cell differentiation, HIF-1, PI3K/AKT other signaling pathways to exert the therapeutic effect through the active ingredients such as gomisin A, linolenic acid, diosmetin, glabridin and myricetin.
CONCLUSION JMD exerts therapeutic effects on AR through multi-component synergy, multi-target action and multi-pathway regulation, and the results of this study provide reference for the subsequent in-depth analysis of pharmacological mechanisms and application in clinical practice.